CD20

Open Access
Cure of Disseminated Human Lymphoma with [²²⁵Ac]Ac-Ofatumumab in a Preclinical Model
Mark S. Longtine, Kyuhwan Shim, Mark J. Hoegger, Nadia Benabdallah, Diane S. Abou, Daniel L.J. Thorek and Richard L. Wahl

Journal of Nuclear Medicine June 1, 2023, 64 (6) 924-931; DOI: https://doi.org/10.2967/jnumed.122.265167
Open Access
Cure of Disseminated Human Lymphoma with [¹⁷⁷Lu]Lu-Ofatumumab in a Preclinical Model
Kyuhwan Shim, Mark S. Longtine, Diane S. Abou, Mark J. Hoegger, Richard S. Laforest, Daniel L.J. Thorek and Richard L. Wahl

Journal of Nuclear Medicine April 1, 2023, 64 (4) 542-548; DOI: https://doi.org/10.2967/jnumed.122.264816
You have access
Noninvasive Evaluation of CD20 Expression Using ⁶⁴Cu-Labeled F(ab′)₂ Fragments of Obinutuzumab in Lymphoma
Lei Kang, Cuicui Li, Zachary T. Rosenkrans, Jonathan W. Engle, Rongfu Wang, Dawei Jiang, Xiaojie Xu and Weibo Cai

Journal of Nuclear Medicine March 1, 2021, 62 (3) 372-378; DOI: https://doi.org/10.2967/jnumed.120.246595
You have access
Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with ⁸⁹Zr in Human Lymphoma Xenografts
Jason T. Yoon, Mark S. Longtine, Bernadette V. Marquez-Nostra and Richard L. Wahl

Journal of Nuclear Medicine August 1, 2018, 59 (8) 1219-1224; DOI: https://doi.org/10.2967/jnumed.117.203299

Main menu